Experiments in development: Time to rethink RCTs?

A community health volunteer gathers health data. While most senior executives who responded to a recent Devex survey aren’t aware of the debate on randomized controlled trials or have no opinion, 70 percent of those who do believe the tool is overhyped. Photo by: Nyaya Health / CC BY

This article is part of The Future of Global Development, a series for Devex Executive Members that explores what development leaders think of the industry’s top issues.

Randomized controlled trials, an impact evaluation method, have been a contentious development issue of late, with as many advocates as critics.

Should your team be reading this?
Contact us about a group subscription to Pro.

About the author

  • Mario villamor 400x400  2

    Mario Villamor

    Mario is a former senior development analyst at Devex's survey and advisory services team. Prior to Devex, Mario was a researcher for the Boston Consulting Group in Boston, Massachusetts, where he supported client engagements in a variety of sectors, including public sector, global health and the social impact space, among others. Before joining BCG, Mario earned his master’s degree in global affairs from New York University.

Join the Discussion